FindTrial
Sign In

To study HER-2/neu over expression in gall bladder cancers

â??To study HER-2/neu over expression in gall bladder cancers -a prospective and retrospective observational studyâ??

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/10/046831
Enrollment
100
Registered
2022-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K828- Other specified diseases of gallbladder

Interventions

None listed

Sponsors

MGUMST
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients presenting with histologically proven gall bladder carcinoma

Exclusion criteria

Exclusion criteria: 1. Whenever it is risky to do biopsy/FNAC like abnormal coagulation profile. 2. Any other histological variant of gall bladder malignancies other than carcinomas.

Design outcomes

Primary

MeasureTime frame
positiveTimepoint: 1 YEAR—

Secondary

MeasureTime frame
HER2 NEU EXPRESSIONTimepoint: 2 YEARS—

Countries

India

Contacts

Public ContactNeha Sethi

MGUMST

nehasethi3@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026